Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma

RATIONALE: The introduction of immune check-point inhibitors (ICIs) in the treatment of solid neoplasms is associated with the need to know and manage a new type of side effects that are commonly defined immune-mediated adverse events. Dermatologic immune-mediated adverse events are relatively commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lolli, Cristian, Medri, Matelda, Ricci, Michela, Schepisi, Giuseppe, Filograna, Alessia, De Giorgi, Ugo, Stanganelli, Ignazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314787/
https://www.ncbi.nlm.nih.gov/pubmed/30593172
http://dx.doi.org/10.1097/MD.0000000000013810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314787/
https://www.ncbi.nlm.nih.gov/pubmed/30593172
http://dx.doi.org/10.1097/MD.0000000000013810

Ejemplares similares